CVS Health Corporation (CVS)
CVS Health: An Attractive 5.8% Safe Yield For Now
Despite significant headwinds and a 43% stock decline, CVS Health's 5.8% dividend yield remains attractive, with a well-covered payout ratio of 55.9%. CVS faces strong competition from Amazon, Walmart, and Costco, impacting market share and pushing management to revise cash flow guidance down to $9.0 billion. The company saw double-digit revenue growth in two of its three segments, with a slight increase in pharmacy market share to 27.3%.
After Falling More Than 40% in 2024, Can CVS Health Stock Turn Things Around This Year?
CVS Health (CVS 0.50%) is a stock that's been struggling badly for multiple years and is coming off a brutal performance in 2024, when its shares nose-dived by 43%.
This Stock Has A 5.81% Yield And Sells For Less Than Book
CVS Health has been named as a Top 25 dividend stock, according the most recent Dividend Channel ''DividendRank'' report. The report noted that among the coverage universe, CVS shares displayed both attractive valuation metrics and strong profitability metrics.
CVS Stock Trades Near 52-Week Low: Should You Buy the Dip?
CVS Health's Medicaid business is experiencing medical cost pressure from higher-than-expected acuity following the resumption of member redeterminations.
CVS Health Corporation (CVS) Is a Trending Stock: Facts to Know Before Betting on It
Recently, Zacks.com users have been paying close attention to CVS Health (CVS). This makes it worthwhile to examine what the stock has in store.
Why 2025 Could Be A Good Reimbursement Year For CVS And Walgreens
Legislation slowly wending its way through states and in Washington could mean increased payments to drugstore chains like CVS Health, Walgreens, Walmart and independent pharmacies across the country.
Why CVS Health (CVS) Outpaced the Stock Market Today
In the latest trading session, CVS Health (CVS) closed at $44.36, marking a +1.32% move from the previous day.
CVS Health has strong position in DOJ case, says TD Cowen
TD Cowen keeps a Buy rating and $80 price target on CVS. The firm says the DOJ complaint relating to opioid prescriptions is incremental to the 2022 settlement with state and local governments for $5B over 10 years. The multi-year impasse between the DOJ and CVS suggests CVS is confident in its case, and while it is unclear what a final settlement figure may be, it may be a fraction of the $5B 10-year settlement that CVS came to with state and local governments in 2022, the analyst tells investors in a research note.
CVS accused of billing the U.S. for illegal opioid prescriptions
The U.S. Department of Justice announced a lawsuit against CVS. Transcript: Conway Gittens: There's a rebound on Wall Street Thursday, one-day after stocks suffered their biggest drops since August.
Reasons to Ratain CVS Stock in Your Portfolio Now
Investors feel optimistic about CVS Health's 2025 roadmap. Yet, poor macroeconomic conditions are concerning.
CVS contributing to US opioid crisis, Justice Department alleges
CVS Health Corp (NYSE:CVS) has been accused by the US Department of Justice of violating the Controlled Substances Act (CSA) and the False Claims Act (FCA). A lawsuit filed in Rhode Island claims CVS knowingly knowingly filled prescriptions for opioids that lacked legitimate medical purposes.
